


PHARMACEUTICAL 2021



CHEMOCENTRYX

ChemoCentryx Inc. Rank 79 of 409





PHARMACEUTICAL 2021





CHEMOCENTRYX

The relative strengths and weaknesses of ChemoCentryx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ChemoCentryx Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 99% points. The greatest weakness of ChemoCentryx Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 61%, being 416% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	441,570
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	51,558
Liabilities, Non-Current	19,057
Other Assets	52,169
Other Compr. Net Income	-204
Other Expenses	0
Other Liabilities	62,671
Other Net Income	-179
Property and Equipment	25,160
Research and Development	77,882
Revenues	64,891
Selling, General and Administrative Expense	42,186

Output Variable	Value in 1000 USD
Assets	518,899
Liabilities	133,286
Expenses	120,068
Stockholders Equity	385,613
Net Income	-55,356
Comprehensive Net Income	-55,458
Economic Capital Ratio	61%